Both vaccines work. But Pfizer requires a longer waiting period before the vaccine kicks in, while Moderna has stronger side effects.

Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast pipeline. Considering the full picture, now, with the stock down 80% over ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective. The ...

MOUNTAIN VIEW, Calif. -- It was the second shot California resident Veena Thomas had been for waiting for. Instead of relief what she felt was panic after the needle was pulled out. RELATED: Here's ...

CHICAGO (WLS) -- The Johnson & Johnson vaccine continues to be put on hold after a CDC panel said it needs more time to look into claims of dangerous blood clots. The United Center mass vaccination ...

Shares in some of America’s largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and ...

The U.S. is in "big danger" of falling behind in vaccine technology research as government funding declines and vaccine ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD treatment was rejected by an FDA advisory committee. Pfizer's PD-1xVEGF deal ...

FRANKFURT (Reuters) - Moderna and Pfizer-BioNTech are in a tight race to launch their COVID-19 vaccines in Europe after both applied for emergency EU approval on Tuesday, though there was uncertainty ...

Pfizer, BioNTech request EU conditional approval Regulator says panel to meet Dec 29 at latest Rival Moderna also submits EU filing for its shot Both groups have applied for U.S. emergency use ...